MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
News|Articles|July 2, 2008
- Pharmaceutical Technology-07-02-2008
- Volume 32
- Issue 7
Trends: Industry Job Cuts
Author(s)Angie Drakulich
Staff reductions are not surprising with the state of the economy and falling pharmaceutical sales.
Advertisement
Given the current state of the economy and the fact that pharmaceutical sales have been crunched over the past several years, job cuts are not surprising. The US unemployment rate has gone up a full percentage point in the past year, from 4.5% in May 2007 to 5.5% in May 2008; the rate in New Jersey went up from 4.3% to 5.0%. Below is a look at some of the largest cuts that pharmaceutical companies—nearly half of them based in New Jersey—have announced since early 2007.
(Raymond Medici/Getty Images, Cartesia/Getty Images)
Companies and announced job cuts
Articles in this issue
over 18 years ago
Coming Down the Pike: Protein-Substrate Bindingover 18 years ago
Self-Emulsifying Drug Delivery Systemsover 18 years ago
A Path to Quality and Complianceover 18 years ago
Excipients in Polymeric Drug Delivery and Formulationsover 18 years ago
ePedigree: Using the Gift of Time Wiselyover 18 years ago
Variables Affecting Reconstitution Time of Dry Powder for Injectionover 18 years ago
Report From: The Netherlandsover 18 years ago
Manufacturing Insights: Pfizerover 18 years ago
Inside IPEC: Dual-Use LabelingAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
2
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
3
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
4
First-in-Human Trial Speed: Why FDA Trails China
5